OVEREXPRESSION OF HER2/NEU ONCOGENE IN HUMAN PANCREATIC-CARCINOMA

被引:203
作者
YAMANAKA, Y
FRIESS, H
KOBRIN, MS
BUCHLER, M
KUNZ, J
BEGER, HG
KORC, M
机构
[1] UNIV CALIF IRVINE,DEPT MED,DIV ENDOCRINOL & METAB,C240,IRVINE,CA 92717
[2] UNIV CALIF IRVINE,DEPT BIOL CHEM,IRVINE,CA 92717
[3] UNIV ULM,DEPT GEN SURG,W-7900 ULM,GERMANY
[4] NIPPON MED COLL,DEPT SURG,TOKYO 113,JAPAN
关键词
IMMUNOHISTOCHEMISTRY; IN-SITU HYBRIDIZATION; NORTHERN BLOT ANALYSIS; SOUTHERN BLOT ANALYSIS; CLINICOPATHOLOGICAL PARAMETERS;
D O I
10.1016/0046-8177(93)90194-L
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The HER2/neu oncogene encodes a transmembrane protein that possesses intrinsic tyrosine kinase activity. Its overexpression has been associated with the malignant phenotype. In this study we examined HER2/neu expression in the normal and cancerous human pancreas. In the normal pancreas HER2/neu immunostaining was observed in acinar and ductal cells. HER2/neu immunoreactivity was expressed in 34 of 76 (45%) pancreatic carcinomas. There was a significant correlation between tumors with well-differentiated histology and HER2/neu expression. Northern blot analysis demonstrated HER2/neu mRNA expression in the normal pancreas and in situ hybridization confirmed its distribution in both acinar and ductal cells. In cancer tissues Northern blot analysis indicated that HER2/neu mRNA levels were elevated in 13 of 25 (52%) of the tumors in comparison with the normal tissues. In addition, in situ hybridization demonstrated a strong but heterogenous distribution of mRNA grains in these tumors. Southern blot analysis did not demonstrate HER2/neu gene amplification in any of the tumors. These data indicate that the HER2/neu protein is synthesized in the normal exocrine pancreas and is frequently overexpressed in well-differentiated adenocarcinomas of the pancreas as a result of increased HER2/neu mRNA levels. © 1993.
引用
收藏
页码:1127 / 1134
页数:8
相关论文
共 44 条
[1]   ABNORMALITIES OF THE P53 TUMOR SUPPRESSOR GENE IN HUMAN PANCREATIC-CANCER [J].
BARTON, CM ;
STADDON, SL ;
HUGHES, CM ;
HALL, PA ;
OSULLIVAN, C ;
KLOPPEL, G ;
THEIS, B ;
RUSSELL, RCG ;
NEOPTOLEMOS, J ;
WILLIAMSON, RCN ;
LANE, DP ;
LEMOINE, NR .
BRITISH JOURNAL OF CANCER, 1991, 64 (06) :1076-1082
[2]  
BEAZLEY RM, 1981, CA-CANCER J CLIN, V38, P310
[3]  
BERGER MS, 1988, CANCER RES, V48, P1238
[4]  
BLICK M, 1984, BLOOD, V64, P1234
[5]   GENERAL METHOD FOR ISOLATION OF HIGH MOLECULAR-WEIGHT DNA FROM EUKARYOTES [J].
BLIN, N ;
STAFFORD, DW .
NUCLEIC ACIDS RESEARCH, 1976, 3 (09) :2303-2308
[6]  
BOS JL, 1989, CANCER RES, V49, P4682
[7]   TYROSINE KINASE RECEPTOR WITH EXTENSIVE HOMOLOGY TO EGF RECEPTOR SHARES CHROMOSOMAL LOCATION WITH NEU ONCOGENE [J].
COUSSENS, L ;
YANGFENG, TL ;
LIAO, YC ;
CHEN, E ;
GRAY, A ;
MCGRATH, J ;
SEEBURG, PH ;
LIBERMANN, TA ;
SCHLESSINGER, J ;
FRANCKE, U ;
LEVINSON, A ;
ULLRICH, A .
SCIENCE, 1985, 230 (4730) :1132-1139
[8]   THE NEU-ONCOGENE PROTEIN AS A PREDICTIVE FACTOR FOR HAEMATOGENOUS METASTASES IN BREAST-CANCER PATIENTS [J].
DEPOTTER, CR ;
BEGHIN, C ;
MAKAR, AP ;
VANDEKERCKHOVE, D ;
ROELS, HJ .
INTERNATIONAL JOURNAL OF CANCER, 1990, 45 (01) :55-58
[9]   CHARACTERIZATION OF A NEU/C-ERBB-2 PROTEIN-SPECIFIC ACTIVATING FACTOR [J].
DOBASHI, K ;
DAVIS, JG ;
MIKAMI, Y ;
FREEMAN, JK ;
HAMURO, J ;
GREENE, MI .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (19) :8582-8586
[10]   C-ERBB-2 ONCOGENE PRODUCT STAINING IN GASTRIC ADENOCARCINOMA - AN IMMUNOHISTOCHEMICAL STUDY [J].
FALCK, VG ;
GULLICK, WJ .
JOURNAL OF PATHOLOGY, 1989, 159 (02) :107-111